Quarterly and annual results disclosed under 8-K Item 2.02.
Mativ Holdings, Inc. reported the three months ended March 31, 2024 results: revenue $500.2 million, net income GAAP loss was $(28.0) million, EPS GAAP EPS was $(0.52).
“Sales of $500.2 million increased 10.6% sequentially versus Q4 2023, and decreased 8.9% versus the prior year, reflecting sequential volume recovery • GAAP loss was $(28.0) million, GAAP EPS was $(0.52), which included organizational realignment, integration and purchase accounting expenses”
Mativ Holdings, Inc. reported the quarter ended March 31, 2024 results: revenue $500.2 million.
“statements for all fiscal quarters of 2023 revised to align with the new segment reporting structure. Mativ First Quarter 2024 Highlights (Continuing Operations) • Sales of $500.2 million increased 10.6% sequentially versus Q4 2023, and decreased 8.9% versus the prior year, reflecting sequential volume recovery • GAAP loss was $(28.0) million, GAAP EPS was”
STURM RUGER & CO INC reported first quarter ended March 30, 2024 results: revenue net sales were $136.8 million, EPS diluted earnings were 40¢ per share.
“for the first quarter of 2024, net sales were $136.8 million and diluted earnings were 40¢ per share.”
MANITOWOC CO INC reported the three months ended March 31, 2024 results: revenue $495.1 million, net income $4.5 million, EPS $0.12 per diluted share.
“The Manitowoc Company, Inc. (NYSE: MTW) (the “Company” or “Manitowoc”) today reported first-quarter net income of $4.5 million, or $0.12 per diluted share. First-quarter adjusted net income (1) was $5.1 million, or $0.14 per diluted share. Net sales in the first quarter decreased 2.6% year-over-year to $495.1 million.”
SUPERIOR GROUP OF COMPANIES, INC. reported the quarter ended March 31, 2024 results: revenue $138.8 million, net income $3.9 million, EPS $0.24 per diluted share. Guidance raised.
“--- EX-99.1 2 ex_645944.htm EXHIBIT 99.1 ex_645944.htm Exhibit 99.1 FOR IMMEDIATE RELEASE SUPERIOR GROUP OF COMPANIES REPORTS FIRST QUARTER 2024 RESULTS – Total net sales of $138.8 million up from $130.8 million in prior year first quarter – – Net income of $3.9 million up from $0.9 million in prior year first quarter – – EBITDA of $9.6 million up from $6.9 million”
Service Properties Trust reported financial results for the quarter ended March 31, 2024.
“On May 7, 2024, Service Properties Trust, or the Company, issued a summary press release and a detailed earnings presentation announcing the Company's financial results for the quarter ended March 31, 2024.”
OPKO HEALTH, INC. reported three months ended March 31, 2024 results: revenue $173.7 million, net income $81.8 million, or $0.12 per share, EPS $0.12 per share.
“was $34.4 million in the first quarter of 2024 compared with $40.0 million in the 2023 period. ● Consolidated: Consolidated total revenues for the first quarter of 2024 were $173.7 million compared with $237.6 million for the comparable period of 2023. Operating loss for the first quarter of 2024 increased to $71.5 million from $30.6 million for the 2023 quarter,”
MASIMO CORP reported first quarter ended March 30, 2024 results: revenue $492.8 million, net income $18.9 million, EPS $0.35 per diluted share. Guidance raised.
“by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Masimo Reports First Quarter 2024 Financial Results First Quarter 2024 Highlights: • Consolidated revenue was $492.8 million; • Healthcare revenue was $339.6 million; • Non-healthcare revenue was $153.2 million; • GAAP net income per diluted share was $0.35; and • Non-GAAP net income per diluted share”
FLOTEK INDUSTRIES INC/CN/ updated its full year 2024 guidance (initiated).
“Flotek expects 2024 adjusted gross profit margin (2) to range between 18% and 22%, as compared to 2023 adjusted gross profit margin (1) of 15%. The Company expects 2024 adjusted EBITDA (2) to range between $10 million and $16 million as compared to $1.5 million in 2023 (1).”
FLOTEK INDUSTRIES INC/CN/ reported the quarter ended March 31, 2024 results: revenue $ 40,374, net income $ 1,562, EPS $ 0.05 per diluted share.
“Total Revenues $ 40,374 $ 48,007 (16)% Gross Profit $ 8,821 $ 1,880 369% Adjusted Gross Profit (1) $ 10,075 $ 2,647 281% Net Income $ 1,562 $ 21,343 (93)% Diluted Income (Loss) Per Share $ 0.05 $ (0.12) n/a”
MCKESSON CORP reported preliminary financial results for the quarter and fiscal year ended on March 31, 2024.
“On May 7, 2024, McKesson Corporation (“Company”) reported the Company’s preliminary results for the quarter and fiscal year ended on March 31, 2024”
ADTRAN Holdings, Inc. reported first quarter of 2024 results: net income GAAP net loss attributable to the Company for the first quarter of 2024, including the above mentioned impairment charge, EPS Diluted loss per share attributable to the Company for the first quarter was $4.12. Guidance reaffirmed.
“GAAP net loss attributable to the Company for the first quarter of 2024, including the above mentioned impairment charge, was $324.6 million. Diluted loss per share attributable to the Company for the first quarter was $4.12.”
SCANSOURCE, INC. reported third quarter ended March 31, 2024 results: revenue $ 752,599, net income $ 12,806, EPS $ 0.50. Guidance reaffirmed.
“the third quarter ended March 31, 2024. Third Quarter Summary Q3 FY24 Q3 FY23 Change (in thousands, except percentages and per share data) Select reported measures: Net sales $ 752,599 $ 885,519 -15.0% Gross profit $ 94,481 $ 111,762 -15.5% Gross profit margin % 12.55 % 12.62 % -7bp Operating income $ 17,542 $ 34,279 -48.8% GAAP net income $ 12,806 $ 21,221”
Armata Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 7, 2024, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three months ended March 31, 2024, in the press release furnished hereto as Exhibit 99.1.”
INNODATA INC reported first quarter ended March 31, 2024 results: revenue $26.5 million, net income $1.0 million, or $0.03 per basic and diluted share. Guidance raised.
“Least 40% Organic Revenue Growth in 2024 NEW YORK – May 7, 2024 – INNODATA INC. (Nasdaq: INOD) today reported results for the first quarter ended March 31, 2024. · Revenue was $26.5 million, up 41% from $18.8 million in the same period last year. · Net income was $1.0 million, or $0.03 per basic and diluted share, compared to a net loss of $(2.1) million, or $(0.08)”
MYRIAD GENETICS INC reported first quarter ended March 31, 2024 results: revenue $202.2 million, net income $26 million, EPS $(0.29). Guidance reaffirmed.
“Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA Highlights: • First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year”
VAALCO ENERGY INC /DE/ reported the first quarter of 2024 results: net income $7.7 million ($0.07 per diluted share), EPS $0.07 per diluted share. Guidance reaffirmed.
“VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) ("VAALCO" or the "Company") today reported operational and financial results for the first quarter of 2024.”
Theriva Biologics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 7, 2024, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended March 31, 2024.”
LIGAND PHARMACEUTICALS INC reported 2024 results: revenue $130 million to $142 million, EPS approximately $4.25 to $4.75. Guidance reaffirmed.
“Ligand is reaffirming its 2024 financial guidance. The Company expects 2024 royalties ranging from $90 million to $95 million, sales of Captisol to range from $25 million to $27 million, and contract revenue ranging from $15 million to $20 million. These revenue components result in total revenue forecast of $130 million to $142 million. Ligand notes that with total revenue of $130 million to $142 million, core adjusted earnings per diluted share are expected to range from approximately $4.25 to $4.75.”
LIGAND PHARMACEUTICALS INC reported the three months ended March 31, 2024 results: revenue $31.0 million, net income $86.1 million, EPS $4.75 per diluted share.
“Total revenues and other income for the first quarter of 2024 were $31.0 million, compared with $44.0 million for the same period in 2023. Royalties for the first quarter of 2024 were $19.1 million, compared with $17.6 million for the same period in 2023, with the increase primarily attributable to Amgen’s (Nasdaq: AMGN) Kyprolis, Jazz Pharmaceuticals' (Nasdaq: JAZZ) RYLAZE, Merck and Co.’s (NYSE: MRK) VAXNEUVANCE and Travere Therapeutics’ (Nasdaq: TVTX) FILSPARI, partially offset by a decline in CASI’s (Nasdaq: CASI) EVOMELA. Captisol sales were $9.2 million for the first quarter of 2024, compared with $10.6 million for the same period in 2023, with the change due to the timing of customer orders. Contract revenue and other income was $2.7 million for the first quarter of 2024, compared with $15.7 million for the same period in 2023, with the difference driven by a $15.3 million milestone payment earned from Travere Therapeutics upon the FDA approval of FILSPARI in the prior year quar”
Pediatrix Medical Group, Inc. reported the three months ended March 31, 2024 results: revenue $495.1 million, net income $4.0 million, EPS $0.05 per diluted share. Guidance reaffirmed.
“ended March 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.20. For the 2024 first quarter, Pediatrix reported the following results: • Net revenue of $495 million; • Net income of $4 million; and • Adjusted EBITDA of $37 million. “Our first quarter operating results were in line with our expectations,” said James D. Swift, M.D., Chief”
U S PHYSICAL THERAPY INC /NV updated its the first quarter ended March 31, 2024 guidance (raised).
“On May 7, 2024 – U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, reported results for the first quarter ended March 31, 2024.”
Orthofix Medical Inc. reported the first quarter ended March 31, 2024 results: revenue $188.6 million, net income $(36.0) million, EPS $(0.95). Guidance raised.
“assets, and any impairment of acquired goodwil --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Orthofix Reports First Quarter 2024 Results Recent Highlights • Net sales of $188.6 million, an increase of 7.7% on a reported basis and 7.5% on a constant currency basis over prior year • Bone Growth Therapies net sales growth of 10%, marking five consecutive quarters”
IONIS PHARMACEUTICALS INC updated its first quarter ended March 31, 2024 guidance (reaffirmed).
“On May 7, 2024, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.”
ARTESIAN RESOURCES CORP reported financial results for first quarter of 2024.
“On May 6, 2024, Artesian Resources Corporation (“Artesian Resources” or the “Company”) issued a press release announcing its earnings for the first quarter ended March 31, 2024.”
Dorman Products, Inc. reported first quarter ended March 30, 2024 results: revenue $468.7 million, EPS $1.05. Guidance reaffirmed.
“• Net sales of $468.7 million, up 0.4% compared to $466.7 million • Diluted earnings per share (“EPS”) of $1.05, up 483% compared to $0.18”
FUEL TECH, INC. reported first quarter (Q1 2024) ended March 31, 2024 results: revenue $5.0 million, net income $281,000, EPS $0.01 per share.
“Q1 2024 Consolidated Results Overview Consolidated revenues for Q1 2024 declined to $5.0 million from $7.3 million in the three months ended March 31, 2023 (Q1 2023), with reductions in both business segments from the prior year period.”
POWER INTEGRATIONS INC reported second quarter of 2024 results: revenue $105 million plus or minus $5 million. Guidance initiated.
“Revenues are expected to be $105 million plus or minus $5 million.”
POWER INTEGRATIONS INC reported first quarter of 2024 results: revenue $91.7 million, net income $4.0 million, EPS $0.07 per diluted share.
“Net revenues for the first quarter were $91.7 million, up two percent from the prior quarter and down 14 percent from the first quarter of 2023. GAAP net income for the first quarter was $4.0 million or $0.07 per diluted share compared to $0.25 per diluted share in the prior quarter and $0.12 per diluted share in the first quarter of 2023.”
Inuvo, Inc. reported Q1 2024 results: revenue $17.0 million, net income $2.1 million, or $0.02 per basic and diluted share, EPS $0.02 per basic and diluted share.
“Inuvo Reports 44% Year-Over-Year Revenue Growth to $17.0 Million for the First Quarter of 2024”
REGAL REXNORD CORP reported first quarter ended March 31, 2024 results: revenue $1,547.7 million, net income $20.4 million, EPS $0.30.
“Adjusted Diluted EPS* Of $2.00 • Adjusted Free Cash Flow* Of $64.6 Million; On Track To Full Year Outlook Of $700 Million • Paid Down $135.0 Million Of Gross Debt • Sales Of $1,547.7 Million, Up 26.4% Versus PY, Down 7.5% On A Pro Forma Organic Basis • GAAP Gross Margin Of 35.7%; Adjusted Gross Margin* Of 36.5% Versus PY Of 33.5% On A Pro Forma Basis* • GAAP Net”
INTERPARFUMS INC reported first quarter ended March 31, 2024 results: revenue Net Sales $324, net income Net Income attributable to IP $41, EPS Diluted EPS $1.27. Guidance reaffirmed.
“the first quarter ended March 31, 2024. First Quarter 2024 Highlights: ($ in millions, except per share amounts) Three Months Ended March 31, 2024 2023 % Change Net Sales $324 $312 4% Gross Margin 62.5% 65.1% (260 bps) Operating Income $68 $90 (25%) Operating Margin 21.0% 29.0% (800 bps) Net Income attributable to IP $41 $54 (24%) Diluted EPS”
PAR PACIFIC HOLDINGS, INC. reported first quarter ended March 31, 2024 results: net income Net Loss of $(3.8) million, EPS $(0.06) per diluted share.
“Par Pacific reported a net loss of $(3.8) million, or $(0.06) per diluted share, for the quarter ended March 31, 2024”
HERON THERAPEUTICS, INC. /DE/ reported three months ended March 31, 2024 results: revenue Net Product Sales of $34.7 million, EPS Net Loss Per Share $(0.02). Guidance reaffirmed.
“Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023.”
Andersons, Inc. reported the first quarter ended March 31, 2024 results: net income net income attributable to The Andersons of $6 million, EPS $0.16 per diluted share.
“The Andersons, Inc. (Nasdaq: ANDE) announces financial results for the first quarter ended March 31, 2024. First Quarter Highlights: • Company reported net income attributable to The Andersons of $6 million, or $0.16 per diluted share;”
Santander Holdings USA, Inc. reported First Quarter 2024 results: revenue $1.2 billion.
“a1q24shusafixedincomepre 1 May 6, 2024 SANTANDER HOLDINGS USA, INC. First Quarter 2024 Fixed Income Investor Presentation 2 This presentation of Santander Holdings USA, Inc. (“SHUSA”) contains”
OCCIDENTAL PETROLEUM CORP /DE/ reported the first quarter of 2024 results: net income $718 million, EPS $0.75 per diluted share.
“Occidental (NYSE: OXY) today announced net income attributable to common stockholders for the first quarter of 2024 of $718 million, or $0.75 per diluted share”
HALLADOR ENERGY CO reported first quarter 2024 results: revenue $ 109,672, net income $ (1,696 ), EPS $(0.05) basic earnings per share.
“represents some of our critical metrics (in thousands, except for per-ton data): Three Months Ended March 31, 2024 2023 Net income (loss) $ (1,696 ) $ 22,051 Total Revenues $ 109,672 $ 188,334 Tons Sold (after elimination) 892 1,693 Average Price per Ton (after elimination) $ 55.64 $ 55.88 Tons Sold (before elimination) 1,214 1,693 Average Price per Ton”
JACK HENRY & ASSOCIATES INC reported Full year fiscal 2024 results: revenue $2,215 $2,228, EPS $5.15 $5.19. Guidance raised.
“Full year fiscal 2024 guidance : 2 Current Previous GAAP Low High Low High Revenue updated $2,215 $2,228 $2,215 $2,228 Operating margin 21.9% 22.0% 21.8% 21.9% EPS updated $5.15 $5.19 $5.09 $5.13”
JACK HENRY & ASSOCIATES INC reported the fiscal nine months ended March 31, 2024 results: EPS $3.85 per diluted share.
“GAAP EPS was $3.85 per diluted share for the fiscal nine months ended March 31, 2024, compared to $3.68 in the prior fiscal year period.”
JACK HENRY & ASSOCIATES INC reported the fiscal three months ended March 31, 2024 results: EPS $1.19 per diluted share.
“GAAP EPS was $1.19 per diluted share for the fiscal three months ended March 31, 2024, compared to $1.12 in the prior fiscal year quarter.”
ELECTRONIC ARTS INC. reported preliminary financial results for fourth fiscal quarter and fiscal year ended March 31, 2024.
“On May 7, 2024, Electronic Arts Inc. ("Electronic Arts" or “EA”) issued a press release announcing its financial results for the fourth fiscal quarter and fiscal year ended March 31, 2024.”
CIRRUS LOGIC, INC. reported Q1 FY25 results: revenue $290 million to $350 million.
“Business Outlook – First Quarter FY25 • Revenue is expected to range between $290 million and $350 million; • GAAP gross margin is forecasted to be between 49 percent and 51 percent; and • Combined GAAP R&D and SG&A expenses are anticipated to range between $142 million and $148 million, including approximately $22 million in stock-based compensation expense and $2 million in amortization of acquired intangibles, resulting in a non-GAAP operating expense range between $118 million and $124 million.”
CIRRUS LOGIC, INC. reported full fiscal year 2024 results: revenue $1.79 billion, EPS $4.90 GAAP and non-GAAP earnings per share of $6.59.
“Reported Financial Results – Full Fiscal Year 2024 • Revenue of $1.79 billion; • GAAP and non-GAAP gross margin of 51.2 percent and 51.3 percent; • GAAP operating expenses of $572.6 million and non-GAAP operating expenses of $470.4 million; and • GAAP earnings per share of $4.90 and non-GAAP earnings per share of $6.59.”
CIRRUS LOGIC, INC. reported Q4 FY24 results: revenue $371.8 million, EPS $0.81 GAAP and non-GAAP earnings per share of $1.24.
“Reported Financial Results – Fourth Quarter FY24 • Revenue of $371.8 million; • GAAP and non-GAAP gross margin of 51.8 percent and 51.9 percent; • GAAP operating expenses of $140.2 million and non-GAAP operating expenses of $116.5 million; and • GAAP earnings per share of $0.81 and non-GAAP earnings per share of $1.24.”
JACOBS SOLUTIONS INC. reported fiscal 2024 results: EPS $7.80 to $8.10.
“The Company has narrowed its outlook for fiscal 2024 adjusted EBITDA to a range of $1,540M to $1,585M and adjusted EPS of $7.80 to $8.10, up 9% and 10% year-over-year at the midpoints, respectively.”
JACOBS SOLUTIONS INC. reported quarter ended March 29, 2024 results: revenue $4.3 billion, EPS $1.29.
“Revenue of $4.3 billion up 4.7% y/y; adjusted net revenue 1 increased 2.9% y/y”
EXPEDITORS INTERNATIONAL OF WASHINGTON INC reported first quarter 2024 results: revenue $2.2 billion, net income $169 million, EPS $1.17.
“Expeditors International of Washington, Inc. (NYSE:EXPD) today announced first quarter 2024 financial results including the following comparisons to the same quarter of 2023: • Diluted Net Earnings Attributable to Shareholders per share (EPS 1 ) decreased 19% to $1.17 • Net Earnings Attributable to Shareholders decreased 25% to $169 million • Operating Income decreased 22% to $215 million • Revenues decreased 15% to $2.2 billion”
KEY TRONIC CORP reported fourth quarter of fiscal 2024 results: revenue $135 million to $145 million, EPS $0.03 to $0.10 per diluted share. Guidance initiated.
“For the fourth quarter of fiscal 2024, Key Tronic expects to report revenue in the range of $135 million to $145 million and earnings in the range $0.03 to $0.10 per diluted share.”
KEY TRONIC CORP reported first nine months of fiscal year 2024 results: revenue $433.7 million, net income $(0.8) million or $(0.07) per share, EPS $(0.07) per share.
“For the first nine months of fiscal year 2024, total revenue was $433.7 million, compared to $425.5 million in the same period of fiscal year 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.